The most intensively studied autoimmune disorder, type 1 diabetes mellitus (DM1), has attracted perhaps the greatest interest for gene-based therapeutic and prophylactic interventions. The final clinical manifestation of this immunologically and genetically complex disease, the absence of insulin, is the major starting point for almost all the gene therapy modalities attempted to date. Insulin replacement by transplantation of islets of Langerhans or surrogate beta cells is the obvious choice, but the allogeneic nature of the transplants activates potent antidonor immunoreactivity necessitating gene and cell-based immunosuppressive strategies as an alternative to the toxic pharmacologic immunosuppressives indicated for classic solid organ transplants. Accumulating knowledge of the cellular mechanisms involved in onset, however, have yielded promising tolerance induction prophylactic approaches using genes and cells. Despite the early successes in a number of animal models, the true test of efficacy in humans remains to be demonstrated.
INSULIN REPLACEMENT: ALTERNATIVES TO PHARMACOLOGIC INSULIN ADMINISTRATION
Type 1 diabetes mellitus (DM1) is a disease where the insulin-producing cells of the pancreas (beta cells), located within endocrine cell clusters called the islets of Langerhans, are initially rendered dysfunctional by immune cells that ultimately destroy them. In one sense, that only beta cells are the targets, sparing the other endocrine cells, greatly simplifies the therapeutic option, which is total and complete insulin replacement. As a disease, DM1 was considered cured by the middle half of the past century with the crystallization and mass production of extracted bovine and porcine insulin. Even with the advent of recombinant human insulin and its various short-and long-acting analogues, it is clear that insulin has not ''cured'' the disease. It manages the hyperglycemia, but cannot prevent the long-term debilitating cardiovascular, renal, neuronal, and peripheral complications. Results from pancreas transplants demonstrate that the provision of intact endocrine cell clusters is necessary to achieve some semblance of tightly controlled glucose regulation. [1] [2] [3] The delicate technical intricacies involved with pancreas transplantation, along with the limited availability of intact cadaveric donor pancreata, spawned alternative strategies of replacing insulin by physiologic producers of the hormone. The most obvious, and the most extensively studied, method of nonpharmacologic insulin replacement was and continues to be the transplantation of intact islets. [1] [2] [3] Procedurally, islet transplantation is not difficult, but its success is constrained by the physiologic state of the donor pancreas, the isolation procedure, and the immunologic state of the recipient. [1] [2] [3] The most recent data from multicenter islet transplantation procedures confirm its ability to restore normoglycemia and very good glucoregulation. However, these positive outcomes have been tempered by the realization that much more needs to be learned 1 about the biology of islets to avoid the requirement of multiple donors and multiple transplantations to completely restore good glycemic control. [1] [2] [3] Perhaps the most important factor that facilitated the success was the choice of a pharmacologic immunosuppressive regimen eliminating glucocorticoids. [1] [2] [3] Nonetheless, the other agents in the regimen (anti-IL-2 receptor a chain antibody along with tacrolimus and rapamycin) are capable of suppressing beta cell function and in promoting varying degrees of renal toxicity. Although one may experiment with various combinations of immunosuppressives, eventually it is targeted immunosuppression that will provide the best cover for islet transplants or beta cell surrogates from immune rejection. However, it is equally appropriate that transplantation be obviated altogether if the mechanisms of DM1 onset are understood and if tolerance induction strategies can be used in ''at-risk'' individuals.
PREVENTION STRATEGIES
The prevailing theory that DM1 is an autoantigendriven disease is based on the existence of antigenspecific antibodies and T cells. 4, 5 In almost all diabetic humans, antibodies reactive with insulin, glutamic acid decarboxylase or the IA-2 phosphoprotein are predictive and diagnostic. Additionally, the cellular basis of diabetes is demonstrated by T cell populations reactive against discrete or unfractionated islet antigens that are capable of transferring disease to naive recipients, [6] [7] [8] [9] [10] with the most dramatic example being human bone marrow transplantation. 11 Furthermore, genetic association studies strongly support the existence of specific antigens that are recognized in the context of ''diabetogenic'' class II HLA molecules in humans. 12 Associated with this theory is the fact that DM1-prone organisms, especially the nonobese diabetic (NOD) mouse, exhibit anomalies in thymic and peripheral tolerance mechanisms whereby islet-reactive T cells are permitted to survive negative selection and are refractory to peripheral mechanisms of regulation. 13 What the data cannot demonstrate is the trigger that promotes the recognition of the b cells as ''foreign.'' If one were to intervene at key steps in these processes ( Fig. 1) , it would be possible to prevent, or at least to delay, the onset of the disease.
AGENTS OF CELL MANIPULATION
The interventional agent largely depends on the molecular pathway and/or cellular network that the gene therapist desires to manipulate to achieve a beneficial therapeutic or prophylactic outcome. If a specific cell population can promote immune hyporesponsiveness, it will be isolated and expanded to homogeneity. If a cell population requires some augmented activity in the form of gene replacement or enhancement, gene(s) will be introduced by the most efficient delivery method. Of course, combinations of cellular and genetic delivery vehicles can be used depending on the specific effect desired.
GENES AND VECTORS
Gene therapy is the post-1970s term used to describe the various methods of gene transfer technology aimed at achieving a therapeutic objective. The transfer of exogenous DNA to cells and tissues can be achieved by viral or nonviral gene delivery vehicles. Although gene replacement or augmentation may be the most obvious endpoint of gene transfer, suppression of gene expression can be equally beneficial given the knowledge of the target whose function the therapist aims to suppress. Nucleic acids in the form of recombinant plasmid DNA and replication-defective viruses have been the workhorses of gene therapy experiments. Newer applications of nucleic acids include small interfering RNA (siRNA) and peptide nucleic acids (PNAs). [14] [15] [16] [17] [18] [19] [20] The former is quite remarkable in that short, doublestranded RNA whose sequence is complementary to that of a primary RNA transcript can induce the almost total suppression of the cognate gene mainly through RNA degradation pathways. [14] [15] [16] [17] [18] PNAs are newer oligonucleotide analogues that are more stable and more specific than conventional antisense RNAs, which can be delivered into cells to inhibit transcription, RNA processing, and translation of a specific gene product. 19, 20 Closely associated with this technology are protein transduction domains, which have a unique capacity of carrying large protein payloads through cell membranes. 21, 22 Naked oligonucleotides can also be taken up by cells in culture or when injected in vivo, and in almost all instances, the oligonucleotides consist of nuclease-resistant backbone modifications. 23, 24 Most of the oligonucleotide approaches are aimed at taking advantage of gene silencing through antisense mechanisms. 23 Nucleic acid-based gene delivery, however, is not the only modality available by which cells and tissues can be augmented with new genes or with molecules modifying gene expression. Liposome formulations are ever-improving and direct physical administration of nucleic acids by gene gun or electroporation approaches are also available options. [25] [26] [27] [28] [29] [30] [31] [32] Nonetheless, viral vectors have been at the forefront of DM1 gene therapy approaches to engineer islets, beta cell surrogates, immune cells, or specific anatomic sites. In Table 1 , we provide a short list of vectors that have been used in DM1 gene therapy as well as their advantages and disadvantages.
INTERVENTIONS
Conceptually, one can intervene at single or multiple points of diabetes development and progression, including insulin replacement, as shown in Figure 1B . Prophylactic therapies will depend on statistically determined risk criteria that may not isolate or identify all individuals who will succumb to the disease. Additionally, lack of statistical risk may not always translate into protection. Therapeutic strategies will almost always be aimed at providing immune cover to cells and tissues producing insulin in autoimmune hosts. Consequently, it would be advantageous, indeed desirable, to eliminate as much of the autoimmune response as possible. This, however, may not be absolute, given that islet allografts and perhaps xenografts may function and survive despite the presence of an autoimmune state, especially following the induction FIGURE 1. Type 1 diabetes progression. Although much of the immunologic data has been observed in rodent models of type 1 diabetes (NOD mouse and BB rat), the progression is believed to be quite similar in humans. A: Clinical progression. Beta cell mass decreases with age at the time of disease onset. The trigger(s) has been proposed to be of viral or nutritional origin but as yet no firm proof conclusively supports either hypothesis. [270] [271] [272] [273] [274] [275] [276] B: Immunopathology. The continuum of infiltrating immune cells can be broken down into several distinct phases. Macrophages and dendritic cells are believed to contribute to functional impairment of insulin secretion likely through the actions of cytokines. Overt islet beta cell destruction is believed to occur subsequent to T cell infiltration. In red, at the bottom, are potential general therapies that can prevent or regulate the disease progression. Insulin replacement in the form of islet or surrogate insulin-producing cell transfers is indicated when almost all the beta cell mass has been exhausted. Adapted from Eisenbarth. 277 of chimerism by bone marrow cell transfer from the transplant donor. 33-37 Tables 2 and 3 outline the approaches that have shown efficacy in vitro and in animal models.
IMMUNOMODULATION
DM1 is perhaps one of a number of autoimmune diseases where it may be possible to induce tolerance. That Table 2 . Potential immunomodulatory/intervention strategies.
Gene therapy Facilitation of islet transplantation Ex vivo transduction with vectors encoding immunoregulatory transgenes (costimulation blockade, cytokine antagonists, apoptosis inhibitors) Infusion of antiapoptotic/immunoregulatory peptides into transplant recipients pre-and post-transplantation In vivo administration to transplantation site of vectors encoding trophic factors for islets Tolerance induction In vivo immunomodulation using vectors encoding immunosuppressive/tolerogenic transgenes In vivo administration of vectors encoding putative autoantigens Cell therapy Surrogate beta cells Embryonic stem cells differentiated into cells with beta cell characteristics In vivo administration of vectors encoding genes promoting beta cell phenotype in pancreatic/hepatic cells Expansion of progenitor cells ex vivo Therapeutic cloning technology
the autoimmunity is directed against beta cells suggests that one or more molecules expressed by beta cells may be employed to tame the immune system. There are convincing lines of evidence, genetic and immunologic, supporting the concept that beta cell-restricted proteins act as autoantigen triggers of T cells that failed to undergo central or peripheral negative selection. 5, 13, [38] [39] [40] [41] [42] It is now apparent that transfer of immune cells (gene-engineered or not) can halt the progression of diabetes. 43 Different cell types will induce different mechanisms of prophylaxis and at different points of the DM1 continuum (illustrated in Fig. 1 ). The most popular approach to date has been to use bone marrowderived dendritic cells, alone or transduced with a number of viral vectors that encode immunoregulatory genes. Tables 2 and 3 illustrate and reference these approaches. For the most part, dendritic cell transfer has succeeded in significantly delaying diabetes onset in NOD mice. In almost every instance of dendritic cell transfer to prevent diabetes, the mechanism has involved the proliferation and/or survival of regulatory T cell subsets. [44] [45] [46] [47] T cell transfer has also been attempted with mixed results. 43 Clinical translation of autologous immune cell transfer to prevent diabetes is certainly feasible, but the logistics involved limit this approach to specialized centers. Immunomodulation need not involve the transfer of autologous cells but a simple vaccination protocol to mobilize immune cells to achieve a therapeutic goal. A number of studies have shown that injection of DNA plasmid vectors encoding immunosuppressive genes, such as TGF-a and a soluble IFN-g receptor into the Table 3 . Approaches demonstrating proof of concept (with references).
Gene vectors which transduce islets
Adeno-associated virus [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] Episomal DNA [160] [161] [162] [163] [164] Herpes simplex virus 194, 195 Adenovirus [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] HIV-1 [190] [191] [192] Cationic liposomes 162, 163, 173 Baculovirus 196 Peptide fusion domains 21, 22, 197 MoLV retrovirus 189 Genes that promote islet allo-/xenograft survival in vitro and in vivo and/or beta cell survival in culture Antiapoptotic genes: Cytokines: Immunoregulatory genes: bcl-2 183, 185, 194, 198 bcl-xL 22, 199 Heme oxygenase-1 200 Intestinal K cells 107 Hepatocytes/hepatoma cells [261] [262] [263] [264] [265] [266] Skeletal muscle 267 Pituitary cells 268 Adipose 269
Autoantigen transfer: GAD 253 
NK-T cells 237 Others:
Adenovirus E3 proteins 254, 255 Orally administered putative autoantigens (insulin, GAD) 256-258 CD152 259 Complement inhibition 260 muscle of NOD mice can reduce the incidence of DM1. 48, 49 Additional methods involve direct injection of plasmids or viral vectors encoding IL-4 and IL-10 ( Table 3 ). The mechanism for protection is not clear but may involve the suppression of maturation of APC in the periphery as well as the suppression of autoreactive T cell activity prior to and during insulitis. The incomplete penetrance of the protection could very well be due to the nature of the plasmid DNA vector and its low persistence, especially at the sites of injection. Another critical factor that may have influenced this exciting approach is the nature of the cells taking up the plasmid vector. It is possible that the immunosuppressive transgene was expressed in migratory APC at the site of injection of the mice in which protection was achieved, which then could deliver the immunosuppressive protein to peripheral lymphoid organs. In the animals in which no protection was achieved, the vector may have been taken up by other cells like skeletal muscle or fibroblasts, which, by their nonmigratory character, confined the expression of the immunosuppressive transgene locally at the site of injection. To enhance this approach, one could target vectors to APC, by either pseudotyping with envelopes engineered to possess ligands for APC-specific receptors or in cationic formulations into which these APC-specific proteins are conjugated. Bioballistic gene delivery may offer advantages over injection, as a number of studies indicate that Langerhans cells and migratory APC are more efficiently engineered to express a transgene by gene gun delivery. 50,51 Finally, in theory, one could also isolate Langerhans cell progenitors from a patient, expand them ex vivo, engineer them in a manner similar to that described above (ie, multicistronic vectors encoding autoantigen along with immunoregulatory gene products), and introduce them subcutaneously where they will migrate to the peripheral lymph nodes to engage autoreactive T cells.
A number of recent studies demonstrate that DC treatment of NOD mice is prophylactic and the mechanism involves regulatory T cells. [52] [53] [54] [55] [56] The existence of regulatory immune cells has been described as early as 1970. 57, 58 Such cells were shown to be important in regulating immunoreactivity in malignancy, transplantation and autoimmune disorders. [59] [60] [61] [62] [63] [64] [65] [66] The cells have been broadly defined as a/b TCR-positive with antigen recognition. From this point on, their phenotypes and characteristics diverge depending on the experimental model and design. Regulatory T cell populations have been defined according to the cytokine secretion profile (T H 2) and cell surface markers detected by antibody-based methods. Accumulated evidence strongly identifies a subpopulation of regulatory T cells within the CD4 + CD25 + population. 60, 67, 68 These cells have been shown to possess suppressive properties in vitro and in vivo in experimental models of DM1 and transplantation tolerance. 60, 63, [66] [67] [68] [69] [70] [71] [72] It is not fully clear whether the suppression is mediated by soluble factors or if cell contact is directly responsible. 73 CD4 + CD25 + T cells have shown considerable potency in suppressing diabetes in the NOD mouse model. [73] [74] [75] Initial evidence derives from cotransfer studies in which CD4 + T cells from prediabetic mice were able to abrogate transfer of diabetes by diabetogenic cells in immunodeficient recipients. 75, 76 Further investigation identified a suppressive population within the CD4 + CD62L high subpopulation. 73, 77 In NOD mice, the most potent suppressive activity was found within a CD4 + CD25 + (a chain of IL-2 receptor) population that was CD62L high . 62, 70 Depletion studies of CD4 + CD25 + cells and a number of subpopulations confirmed their importance in suppressing development of DM1 in the NOD mouse. [78] [79] [80] [81] [82] [83] [84] Although the precise population remains to be identified, the CD4 + CD25 + subpopulation is about 7%-10% of the total number of CD4 + cells in nondiabetic mouse strains. In the NOD mouse, this number has been shown to be somewhat reduced in some studies but not in others. 85, 86 In addition to CD4 + CD25 + regulatory T cells, others have identified immune cells with different phenotypes capable of suppressing diabetes onset and providing hyporesponsiveness in transplantation strategies including NK-T 87-90 and CD8 + CD28 2 cells. [91] [92] [93] [94] [95] [96] Although the mechanisms of changing the function of the cells that these regulatory T cells interact with are not known, a number of phenotypic changes have been documented including blockade of costimulatory molecule up-regulation on proximal antigen-presenting cells, 96 inhibition of NF-kB nuclear translocation and CD40 signaling. 97, 98 Recent data suggest that these cells, acting through antigen-presenting cells, induce the differentiation of CD4 + CD25 + T cells. [99] [100] [101] [102] [103] Strategies to amplify these low-abundance regulatory T cells from patients with recent-onset diabetes offers an additional means of intervening in the autoimmune process.
TRANSPLANTATION
The transplantation of intact islets of Langerhans, although not a recent idea, was finally realized in worldwide trials following the modification of a standard pharmacologic immunosuppressive regimen. 2, 3 Nonetheless, this was not able to surmount the need for multiple donors and transplants, nor has this modality proven effective in permanent glucohomeostatic control in all recipients. [104] [105] [106] Although a number of reasons could underlie this outcome, including the state of the islets prior to the transplantation procedure, the trauma associated with islet isolation and peritransplantation procedure stress as well as the immunosuppressive drug-induced islet beta cell dysfunction, the concept has been proven clinically effective and this should motivate the discovery of ways to protect the islet transplant without the need for immunosuppressive agents. Philosophically, conferring a shield of immune privilege along with a means of access to nutrients and a way to scavenge free radicals could give islets the long-term survival required to maintain normal glucoregulation.
Local expression of immunoregulatory genes and trophic factors by the islet transplants and/or the site of engraftment could be one way to attain this. For example, factors that promote neovascularization and neoinnervation (like VEGF and NGF) expressed from cells constituting the site of engraftment would render that site ''hospitable'' to the transplant by facilitating nutrient accessibility and neuronal control of insulin production. Second, expression of free-radical scavenging proteins and enzymes by the transplant itself and/or the cells at the site of engraftment would minimize primary graft failure, which in almost all instances is due to the generation of free radicals and reactive oxygen species. Third, the provision of immune privilege (ie, expression of IL-1 and TNF antagonists) would divert the activity and function of infiltrating antigenpresenting cells that are believed to present alloantigen in the context of class II MHC in islet allograft rejection. Table 3 summarizes the various genes transduced into allogeneic islets that have conferred some degree of long-term graft survival and meet the criteria specified in the preceding lines.
SURROGATE BETA CELLS
The ability to identify methods to create surrogate islet beta cells would obviate the requirement of harvesting pancreata from allogeneic cadaveric donors. In this instance, surrogate cells could be maintained, passaged, expanded, and engineered in culture, or made by direct transfer of a glucoregulatory gene into a tissue not subject to autoimmune attack.
A number of cell types have been examined as potential insulin-producing surrogates. Among these are hepatocytes, skeletal muscle, intestinal K cells, and hypothalamic pituitary cells (Table 3 ). Although none of these cells seem to be targeted by autoimmunity, they lack a regulated secretory mechanism that is tightly coupled to glucose sensing, with the exception of K cells and pituitary cells. It has been possible to engineer cells with a variety of vectors encoding modified proinsulin alone or in combination with furin-like proteases and GLUT-2/glucokinase, but regulated secretion was not always tightly coupled to glucose sensing (Table 3 ). K cells, perhaps, are the only cell type that demonstrated good coupling kinetics and may provide fertile ground for further investigation. 107 The discovery of transcriptional regulators of beta cell differentiation from progenitors or related cell types has yielded parallel pathways that can be manipulated to achieve normal glucoregulation in diabetic hosts. The PDX-1 transcription factor, indispensable for the development of beta cells from progenitors, when targeted to the liver of diabetic mice was shown to promote the differentiation of liver-resident cells into insulin-producing cells (Table 3 ). Concurrently, in vivo liver transduction with an adenoviral vector encoding betacellulin and NeuroD/BETA2, or PAX-4, also resulted in the reversal of diabetes (Table 3 ). It should therefore be possible to manipulate transcriptional pathways in progenitor beta cells found in tissues outside of the pancreatic ductal epithelium to induce differentiation of functional beta cells.
The considerable genetic manipulations that are required to convert non-beta cells into efficient glucosesensing, insulin-secreting cells have led other investigators into considering means of expanding adult or neonatal beta cells or of harnessing the developmental potential of islet precursor cells and of embryonal stem cells. However, despite the culture conditions and manipulations, commitment to beta cells and insulin production has not always been consistent. [108] [109] [110] [111] [112] [113] Much excitement has also surrounded observations that adult stem cells from bone marrow or from other tissues could ''transdifferentiate'' into a number of other lineage-different cell types. Such stem cells have been described and sometimes physically isolated in the nervous system, pancreas, epidermis, mesenchyme, liver, bone, muscle, and endothelium. Hematopoietic stem cells in some studies were proven able to yield endothelial, brain, muscle, liver, and mesenchymal cells. In some studies, hematopoietic cells could also be generated from neuronal or muscle stem cells. 114 A number of issues however, have tempered the enthusiasm with which these observations were initially greeted. The contamination of hematopoietic stem cells with mesenchymal precursors, the programming by growth factors in culture, and, more recently, the phenomenon of fusion of stem cells with tissue cells are perhaps the most important variables to better test. 114, 115 Recent developments, however, strengthen the belief that mesenchymal cells in bone marrow may be a multipotent source of cells. [116] [117] [118] This characteristic can be exploited; however, there are no data on whether such cells can be differentiated along the islet and beta cell lineage. Clearly, the ability to manipulate bloodborne progenitors into the beta cell lineage should provide a significant breakthrough for surrogate beta cell technology as insulin replacement.
Despite the current controversy and the serious ethical issues raised by cloning technology, it is likely that therapeutic cloning, under strict and defined conditions, will find its place in stem cell therapies. [119] [120] [121] In this regard, one possible means of propagating beta cells or progenitors while avoiding the complications involved with the immune response could entail the removal of DNA or nucleus from somatic cells of a patient and transfer it into an enucleated embryonal stem cell and its expansion into an appropriate beta cell lineage. Although this remains highly speculative at present, the rapid pace of basic work in this area, despite restrictions, will likely yield insight into such manipulations.
Immortalization of islet cells with a beta cell phenotype has been attempted and successfully achieved. Insulin production, however, seems to be linked to terminal differentiation of the cell, an event normally reached with growth arrest. This problem has so far limited the utility of cell immortalization. Also, this approach carries with it the possibility of oncogenic transformation. [122] [123] [124] [125] Although still controversial, there are data indicating that mature human beta cells can be induced to replicate under the effects of hepatocyte growth factor (HGF). [126] [127] [128] The limitation of this approach, however, rests on the loss of differentiation of the induced beta cell along with a substantial decrease in insulin production. 129 Conditional replication of nonhuman beta cells has been achieved by placing the SV-40 T antigen under the control of an inducible promoter. 123 In these studies, beta cells were able to replicate and to maintain differentiated function under inducible conditions. No data exist on whether such an approach is feasible in human beta cells.
Propagation of islet precursor cells with subsequent genetic manipulation to commit them to the beta cell lineage and ultimately to beta cells has also been considered. 112, 130 To become feasible, this approach, however, requires a more complete understanding of the hierarchy of master regulatory transcriptional genes. Depending on the cell type, PDX-1 overexpression can impart onto it a beta cell or a beta cell-like phenotype. [131] [132] [133] Indeed, Ferber et al 134 demonstrated that adenoviral gene transfer of a PDX-1 gene into liver resulted in insulin-expressing cells, although it was not clear whether these cells were glucose sensitive and were actually secreting the insulin in a timely fashion. Other important transcriptional regulators associated with differentiation of ductal epithelial cells into endocrine islet cells include the HNF family of transcription factors, PAX-4 and PAX-6, NeuroD/B2, Nkx 2.2 and Nkx 6.1. 133, 135, 136 Along with intracellular determinants, precursor cells require signaling from their environment to differentiate appropriately. A variety of polypeptide growth factors including insulin-like growth factors I and II, [137] [138] [139] [140] [141] prolactin, 142 placental lactogen, 143, 144 parathyroid hormone-related peptide, 145, 146 and, to a limited extent, TGF-a 139, 147, 148 can promote pancreatic cell growth and islet cell proliferation. Hart and colleagues 149, 150 have produced evidence suggesting that fibroblast growth factor (FGF) signaling is important for beta cell generation. Strategies aimed at engineering beta cell progenitors from pancreatic ductular epithelium with FGF in the presence of a permissive PDX-1 expression could promote expansion of beta cell progenitors or a differentiation of progenitors into a pre-beta cell lineage.
Another class of factors has been identified whose expression and production is associated with pancreatic regeneration. [151] [152] [153] The Reg secreted protein, in particular, promotes increases in beta cell mass in rats that had undergone pancreatectomy. [154] [155] [156] The expression and secretion of another molecule that belongs to the Reg family of proteins, termed INGAP (islet neogenesis associated protein), are up-regulated in hamster islets where neogenesis was artificially induced. 157, 158 The precise role of INGAP on beta cell proliferation and function, however, remains unclear.
Very recently, Bonner-Weir and colleagues 159 have shown that it may be feasible to derive beta cell cluster buds from exocrine pancreatic tissue from which originate the ductular epithelial cells destined to become endocrine pancreatic islet cells. This approach is exciting in that mature, nonendocrine tissue of the pancreas need not be wasted during the process of islet isolation, but can be used in defined culture systems to generate islet progenitor cells for further manipulation, genetic or hormonal.
Thus, taken together, the transfer of combinations of genes encoding soluble and intracellular differentiation factors to stem/progenitor cells could become feasible once their precise role in the pathway of commitment and differentiation to beta cells becomes clearer. However, beta cells have a limited life span in vitro. To what extent apoptosis or senescence plays a role in this is uncertain. Nonetheless, a better understanding of cell cycle control in beta cells or neonatal islet cells could lead to the discovery of molecules that could be exploited, in a conditional manner, to promote growth in vivo and maintenance or extension of life span, both in vitro and in vivo. Possible means include the transfer of cyclin-dependent kinases, proreplication and mitotic factors, and/or telomerase to promote expanded cell life span, all under regulatable promoters. Such an approach could achieve the expansion of semicommitted or fully committed islet precursor cells or early beta cells.
FUTURE GOALS/OPTIONS
Currently, islet allotransplantation offers the best promise for long-term maintenance of normoglycemia within a window that is predicted to minimize the onset of complications. The 2 immediate hurdles facing islet transplantation are the shortage of cadaveric donors and the immune rejection. Undoubtedly, the facile solution for the latter is to pursue combination pharmacologic immunosuppression. Nevertheless, safety trials should be initiated on transplantation of islets engineered with recombinant adenoviral vectors expressing a marker gene. This will prove the concept in humans and will yield important insight into the response of the recipient's immune system against the vector. Immediately thereafter, safety studies should begin in transplanting islets transduced with vectors encoding immunoregulatory genes.
There is currently no facile solution to the shortage of allogeneic cadaveric donors. Xenotransplantation is certainly an option, given the recent success of cloning pigs with a homozygous deletion of the a(1,3)galactosyltransferase, but there are certainly many unknown xenoantigens about which we have no information on the mechanisms of their interaction and reaction with the recipient's immune system. Stem cells, from adult and embryonic tissues as well as from therapeutic cloning, offer theoretical solutions to both the shortage of donor organs and the immune rejection, but this therapeutic possibility remains a distant prospect given our poor knowledge of stem cell differentiation and commitment, as well as the ethical questions posed by research on embryonic stem cells and therapeutic cloning.
At the conceptual level, many of the approaches reviewed herein have proven efficacious in the treatment of diabetes. It is time that these modalities enter safety testing in humans. 
